iX Biopharma – The Year of the Unicorn , BUY Rating with S$1.00 Target Price April 24, 2026

Company Overview

iX Biopharma Ltd is a pharmaceutical company founded in 2008 and listed on SGX Catalist in 2015. The company specialises in proprietary drug delivery technologies, WaferiX and WaferlogiX, which enable sublingual delivery of therapeutics with enhanced bioavailability and rapid absorption. With a pipeline of over 30 pharmaceutical drugs and 7 nutraceutical products, iX operates a manufacturing facility in Melbourne, Australia. The company’s lead drug, Wafermine, is a ketamine-based wafer for pain management that has successfully completed Phase 2b clinical trials.

Major DoD Funding Validates Technology Platform

iX Biopharma has achieved a significant milestone by securing US$41 million in funding from the US Department of Defence (DoD), representing a watershed event that de-risks Wafermine’s final Phase 3 development. This funding validates the WaferiX technology platform and provides entry into the US$5-6 billion acute pain market in the United States. The DoD endorsement serves as major external validation of the company’s sublingual technology, offering a superior outcome compared to typical Phase 2 out-licensing deals where partners capture the majority of upside.

Immediate Revenue Potential

The near-term revenue driver centres on supplying Wafermine to the DoD under an Emergency Use Authorisation for immediate battlefield deployment and operational military medical use. Initial orders of US$3 million are expected in FY27e. The larger opportunity lies in Wafermine adoption into standard field kits and sales into the non-military commercial market following full US FDA approval.

Additionally, iX is monetising its compound pharmacy operations in the US market, worth US$6 billion. Through partnership with Orion Specialty Labs, the company can supply personalised drugs via a capital-light manufacturing and distribution route, with NAD+ (nicotinamide adenine dinucleotide) serving as the near-term revenue driver.

Investment Recommendation

Phillip Securities Research has re-initiated coverage on iX Biopharma with a BUY recommendation and a sum-of-the-parts derived target price of S$1.00. The research identifies three pathways to monetise Wafermine: full commercialisation upon FDA approval in 1Q29, out-licensing, or an outright sale of the drug. Until Phase 3 trial completion, iX Bio will benefit from three new revenue sources through Wafermine EUA sales, DoD grant funding, and compound pharmacy operations in the US.

Frequently Asked Questions

Q: What is the significance of the US DoD funding for iX Biopharma?
A: The US$41 million DoD funding represents a watershed event that de-risks Wafermine’s Phase 3 development, validates the WaferiX technology platform, and provides access to the US$5-6 billion acute pain market whilst allowing iX to retain full ownership and control.

Q: When are initial DoD orders expected and what revenue potential exists?
A: Initial orders of US$3 million are expected in FY27e under Emergency Use Authorisation. The larger opportunity involves standard field kit adoption and commercial market sales following FDA approval.

Q: What is iX Biopharma’s core business and technology?
A: iX Biopharma is a pharmaceutical company with proprietary WaferiX and WaferlogiX drug delivery technologies enabling sublingual delivery of therapeutics with enhanced bioavailability and rapid absorption, with a pipeline of over 30 pharmaceutical drugs and 7 nutraceuticals.

Q: What are the three pathways to monetise Wafermine?
A: The three pathways are full commercialisation upon FDA approval in 1Q29, out-licencing the drug to partners, or an outright sale of Wafermine to interested parties.

Q: How does the compound pharmacy strategy contribute to revenue?
A: The US compound pharmacy market is worth US$6 billion. Through partnership with Orion Specialty Labs, iX can supply personalised drugs using WaferiX technology without further FDA approvals, with NAD+ as the near-term revenue driver.

Q: What is Phillip Securities Research’s recommendation and target price?
A: Phillip Securities Research has issued a BUY recommendation with a sum-of-the-parts derived target price of S$1.00, applying a 40% discount to Wafermine’s net present value and valuing the compound pharmacy at 20x PE.

Q: What other revenue sources will iX benefit from before Phase 3 completion?
A: Until Phase 3 trial completion, iX will enjoy three new revenue sources: Wafermine EUA sales to the DoD, DoD grant funding for development, and compound pharmacy operations in the US market.

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.

Disclaimer

These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

About the author

Paul Chew

Paul has more than 25 years of experience as a fund manager and sell-side analyst. He currently covers sectors such as healthcare, electronics, telecommunications, conglomerates, small caps, and strategy.

He graduated from Monash University and has completed both his Chartered Financial Analyst and Australian CPA programme.

Yangzijiang Maritime Development Positioned for Growth Amid Shipping Cycle Upswing with BUY Rating and S$0.69 Target Price